import Database from 'better-sqlite3';
import path from 'path';
import { fileURLToPath } from 'url';

const __filename = fileURLToPath(import.meta.url);
const __dirname = path.dirname(__filename);

const dbPath = path.join(__dirname, 'data', 'health.db');
const db = new Database(dbPath);

const insertPaper = db.prepare(`
  INSERT INTO papers (title, authors, journal, publication_date, url, abstract, type)
  VALUES (?, ?, ?, ?, ?, ?, ?)
`);

const title = "Angiostop (Sea Cucumber Extract) Inhibits Multiple Cancer Targets - Multi-RTK Inhibition & Clinical Cases";

const authors = "Tsu-Tsair Chi, NMD, PhD";

const journal = "Townsend Letter";

const publication_date = "2016-12-01";

const url = "https://townsendletter.com/angiostop-sea-cucumber-extract-inhibits-multiple-cancer-targets-chi-sponsored-article/";

const abstract = `Comprehensive review of Angiostop (sea cucumber triterpene glycoside extract) demonstrating multiple anti-cancer mechanisms and clinical applications.

MULTIPLE RTK INHIBITION (5 RECEPTORS):
â€¢ VEGFr - Vascular Endothelial Growth Factor Receptor (angiogenesis)
â€¢ EGFr - Epidermal Growth Factor Receptor (proliferation)
â€¢ PDGFr - Platelet-Derived Growth Factor Receptor (angiogenesis)
â€¢ FGFr - Fibroblast Growth Factor Receptor (angiogenesis)
â€¢ IGFr - Insulin-like Growth Factor Receptor (proliferation/survival)

RGCC TESTING RESULTS (Colon Cancer Patient):
â€¢ IGFr inhibition: 19%
â€¢ FGFr inhibition: 24%
â€¢ VEGFr inhibition: 26%
â€¢ Caspase 3 activation: Increased
â€¢ >10% inhibition = "excellent anti-cancer agent"

IGFr CLINICAL SIGNIFICANCE:
â€¢ No FDA-approved IGFr inhibitor exists
â€¢ IGFr elevated in almost all cancers
â€¢ Hyperinsulinemia increases cancer risk dramatically:
  - Colorectal: +17-42%
  - Gastric: +69-101%
  - Breast: +200-300%
  - Liver: +240%
  - Prostate: +562%
  - Endometrial: +4500%

ANGIOGENESIS INHIBITION:
â€¢ Disrupts all 3 processes: proliferation, migration, tube formation
â€¢ Case: 42-year-old breast cancer, 2 months Angiostop â†’ significant angiogenesis reduction (thermal imaging)
â€¢ Starves tumors â†’ apoptosis

APOPTOSIS INDUCTION:
â€¢ Activates Caspase 3, 7, 8, 9
â€¢ â†‘ Pro-apoptotic: Bax, BAD, Cytochrome C
â€¢ â†“ Anti-apoptotic: Bcl-2, survivin
â€¢ Intrinsic pathway activation

ADDITIONAL MECHANISMS:
â€¢ PTEN activation (tumor suppressor missing in 70% prostate cancers)
â€¢ PGE2 receptor antagonism (EP2/EP4) â†’ reduced metastasis
â€¢ Topoisomerase 2-alpha inhibition (DNA level, no toxicity)
â€¢ Downstream suppression: Akt, ERK, FAK, paxillin

SYNERGY WITH TARGETED DRUGS:

CASE: Angiosarcoma + Sutent
â€¢ 81-year-old, breast angiosarcoma recurrence
â€¢ Sutent alone (even doubled): No effect
â€¢ Sutent reduced + Angiostop added: Cleared in 4 months
â€¢ Reason: Sutent only inhibits VEGFr/PDGFr; Angiostop adds EGFr/FGFr/IGFr

CASE: Kidney Cancer + Sutent
â€¢ Male 60s, Sutent reduced tumor to 2cm
â€¢ Added Angiostop + Revivin: 1cm in 4 months, cleared after 1 year

CASE: Lung Cancer + Tarceva
â€¢ Antoine E., 60-year-old, Stage 4 adenocarcinoma (grapefruit size)
â€¢ Given 3-6 months
â€¢ Tarceva + Angiostop + Myomin + Revivin + others
â€¢ Dec 2013: PET scan NO TUMOR
â€¢ Oncologist: "Only patient on Tarceva living that long" (9 months typical)

CASE: Prostate Cancer
â€¢ Dino F., 51-year-old, PSA 5.9 after testosterone therapy
â€¢ Angiostop + Myomin + Revivin for 1.5 years
â€¢ PSA: 5.9 â†’ 2.8
â€¢ Weight: 298 â†’ 220 lbs

BLADDER CANCER PDX MODELS:
â€¢ PDX B521: Angiostop outperformed Padcev and cisplatin/gemcitabine
â€¢ PDX BLCU-003: Superior efficacy vs Padcev
â€¢ Dose-dependent responses
â€¢ Multiple complete responses

TRIPLE NEGATIVE BREAST CANCER CASE:
â€¢ 52-year-old, Grade 3 ER-/PR-/HER2- invasive ductal carcinoma
â€¢ Declined full-dose chemo after lumpectomy
â€¢ Protocol: Angiostop + Revivin
â€¢ CTC: 9.4 cells/7.5ml â†’ 0 in 3 months
â€¢ All tumor markers normal (CEA, CA 15-3, CA 27-29)
â€¢ RGCC testing showed high risk for VEGFr, FGFr, PDGFr, EGFr â†’ all inhibited by Angiostop

SURGERY PROTECTION:
â€¢ 50% recurrence risk within 2 years after breast/colon/lung surgery
â€¢ Surgery healing triggers angiogenic factors
â€¢ Recommendation: Angiostop BEFORE and AFTER any invasive procedure
â€¢ Critical for biopsy, colonoscopy, endoscopy, cystectomy

COLORECTAL CANCER + AVASTIN/5FU:
â€¢ Patient CEA: 8 â†’ 6.9 after 5 weeks Avastin + 5FU
â€¢ Added Angiostop: CEA 6.9 â†’ 3.6 in 4 weeks
â€¢ Much faster response with Angiostop addition

LONG-TERM USE CASE:
â€¢ 70-year-old smoker, blood in stool
â€¢ Started Angiostop + Myomin + Revivin immediately (June 2011)
â€¢ Sept 2012 (age 65): Lung cancer surgery, no metastasis (surgeon amazed)
â€¢ March 2013: Colon cancer surgery
â€¢ Added Tarceva Jan 2015, continued Angiostop + Myomin
â€¢ CEA well-managed 2013-2016 (4+ years)
â€¢ Quality of life maintained

RESEARCH GENETIC CANCER CENTRE (RGCC) VALIDATION:
â€¢ Greece-based, personalizes testing on CTCs
â€¢ Dr. Ray Hammond: "Very potent, effective on 6-7 cancer types"
â€¢ Tested: breast, lung, prostate, colorectal, pancreatic, liver
â€¢ Consistent inhibition across multiple cancer types

SAFETY PROFILE:
â€¢ Minimal or no side effects
â€¢ Well-tolerated long-term (years of use)
â€¢ No acute toxicity in studies
â€¢ Synergistic with chemo (enhanced effect, no added toxicity)
â€¢ Enhanced gemcitabine in pancreatic cancer
â€¢ Enhanced cisplatin with no side effects
â€¢ Enhanced Avastin + 5FU response

ADVANTAGES OVER SINGLE-TARGET DRUGS:
â€¢ Most targeted drugs: 1-2 RTKs only
â€¢ Angiostop: 5 RTKs simultaneously
â€¢ Cancer expresses multiple RTKs (breast, prostate, lung, colorectal, ovarian, brain, pancreatic = all 5)
â€¢ Single-target = partial suppression â†’ poor prognosis/recurrence
â€¢ Multi-target = comprehensive suppression

CHINESE MEDICINE HISTORY:
â€¢ Used for centuries for stomach ulcer and stomach cancer
â€¢ Modern identification of active compounds: triterpene glycosides
â€¢ Scientific validation of traditional use

CLINICAL TRIAL SYNERGY EVIDENCE:
â€¢ Pancreatic cancer: Sea cucumber enhanced gemcitabine (more effective than either alone)
â€¢ Cisplatin combination: Enhanced activity, no side effects
â€¢ Multiple preclinical models validate synergy

COMPARISON TO ANGIOSTOP:
Unlike drugs with limited RTK targets:
â€¢ Nexavar (kidney/liver/thyroid): Only 3 months survival increase
â€¢ Tarceva (EGFR): 9-10 months effectiveness, then resistance
â€¢ Angiostop: Years of effectiveness, no resistance development

CLINICAL RECOMMENDATIONS:
â€¢ Surgical patients: Start before and continue after procedures
â€¢ Active treatment: Combine with conventional therapy
â€¢ Maintenance: Continue long-term for prevention
â€¢ Low disease burden: Start early for best results

DOSING:
â€¢ Typically 800-1200mg daily in divided doses
â€¢ Higher doses for active disease
â€¢ Maintenance doses for prevention
â€¢ No toxicity dose-limiting factors

FUTURE DIRECTIONS:
â€¢ Larger clinical trials needed
â€¢ Optimal dosing protocols
â€¢ Combination therapy guidelines
â€¢ Biomarker development for response prediction`;

const type = 'integrative';

const info = insertPaper.run(
  title,
  authors,
  journal,
  publication_date,
  url,
  abstract,
  type
);

const paperId = info.lastInsertRowid;

console.log(`âœ“ Added paper: "${title}" (ID: ${paperId})`);

// Add tags
const insertTag = db.prepare(`
  INSERT OR IGNORE INTO tags (name) VALUES (?)
`);

const insertPaperTag = db.prepare(`
  INSERT INTO paper_tags (paper_id, tag_id)
  SELECT ?, id FROM tags WHERE name = ?
`);

const tags = [
  'angiostop',
  'sea-cucumber',
  'triterpene-glycosides',
  'multi-rtk-inhibitor',
  'vegfr',
  'egfr',
  'pdgfr',
  'fgfr',
  'igfr',
  'angiogenesis-inhibition',
  'bladder-cancer',
  'apoptosis',
  'integrative-oncology',
  'natural-compounds',
  'case-reports',
  'synergy-chemotherapy',
  'hyperinsulinemia',
  'metabolic-oncology',
  'surgical-protection',
  'long-term-use'
];

tags.forEach(tag => {
  insertTag.run(tag);
  insertPaperTag.run(paperId, tag);
  console.log(`  âœ“ Tagged: ${tag}`);
});

// Verify
const paper = db.prepare(`
  SELECT p.*, GROUP_CONCAT(t.name, ', ') as tags
  FROM papers p
  LEFT JOIN paper_tags pt ON p.id = pt.paper_id
  LEFT JOIN tags t ON pt.tag_id = t.id
  WHERE p.id = ?
  GROUP BY p.id
`).get(paperId);

console.log('\nðŸ“„ Paper added successfully:');
console.log(`Title: ${paper.title}`);
console.log(`Journal: ${paper.journal}`);
console.log(`URL: ${paper.url}`);
console.log(`Tags: ${paper.tags}`);
console.log(`\nView at: http://localhost:5173/research`);

db.close();
